Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$28.09M
Enterprise Value$1.66M
Total Cash (Recent Filing)$15.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Apr 06, 2026EPS Estimate
-4.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$29.33Price Target Upside261.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SafetyAbsence of amyloid-related imaging abnormalities (ARIA) and serious adverse events in early trial cohorts, combined with DSMB approval to advance to a high-dose cohort, increases confidence in PMN310's superior safety profile versus marketed anti-amyloid antibodies.
Regulatory ProgressFDA Fast Track designation for PMN310 enhances agency engagement and could accelerate clinical development and regulatory review, improving the prospects for a faster path to market.
Scientific Differentiation And Portfolio ExpansionPMN310's high selectivity for toxic beta-amyloid oligomers, preservation of memory in preclinical models, and advancement of additional neurodegenerative candidates toward IND-enabling studies support a differentiated therapeutic profile and meaningful commercial upside.
Bears Say
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $28.09M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Apr 06, 2026 which is in 54 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Nov 12, 2025. The company reported -$6 earnings per share for the quarter, beating the consensus estimate of -$7.25 by $1.25.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -4.66.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$6 in its last earnings report, beating expectations of -$7.25. Following the earnings report the stock price went up 3.949%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$29.33
▲(261.25% Upside)